Synopsis
Synopsis
0
CEP/COS
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 2-hydroxy-n,n,n-trimethylethanaminium
2. Bitartrate, Choline
3. Bursine
4. Chloride, Choline
5. Choline Bitartrate
6. Choline Chloride
7. Choline Citrate
8. Choline Hydroxide
9. Choline O Sulfate
10. Choline O-sulfate
11. Citrate, Choline
12. Fagine
13. Hydroxide, Choline
14. O-sulfate, Choline
15. Vidine
1. Choline Ion
2. Bilineurine
3. 62-49-7
4. Choline Cation
5. 2-hydroxy-n,n,n-trimethylethanaminium
6. Cholinum
7. Ethanaminium, 2-hydroxy-n,n,n-trimethyl-
8. (2-hydroxyethyl)trimethylammonium
9. Trimethylethanolamine
10. N-trimethylethanolamine
11. Vitamin J
12. 2-hydroxyethyl(trimethyl)azanium
13. Ccris 5847
14. Ai3-24208
15. Brn 1736748
16. N,n,n-trimethylethanol-ammonium
17. Chebi:15354
18. (beta-hydroxyethyl)trimethylammonium
19. Chembl920
20. N91bdp6h0x
21. (2-hydroxyethyl)trimethylazanium
22. 2-hydroxy-n,n,n-trimethyl-ethanaminium
23. Bilineurine; Choline Cation; Choline Ion; Nanoveson C; Vitamin J
24. Cht
25. Nsc402838
26. Ncgc00015219-03
27. Einecs 200-535-1
28. Unii-n91bdp6h0x
29. 2-hydroxyethyl(trimethyl)ammonium
30. 1oba
31. 2reg
32. 3ppq
33. Choline (dcf)
34. Choline (8ci)
35. Nanoveson C
36. Spectrum_000258
37. 2ha3
38. 3r6u
39. Choline [vandf]
40. Choline [mi]
41. Spectrum2_001938
42. Spectrum4_000867
43. Spectrum5_001579
44. Lopac-c-1754
45. Choline [who-dd]
46. Bmse000285
47. Bmse000953
48. Bmse001003
49. Epitope Id:116046
50. Schembl3142
51. Lopac0_000180
52. Kbiogr_001533
53. Kbioss_000738
54. 3-04-00-00651 (beilstein Handbook Reference)
55. Divk1c_000107
56. N,n,n-trimethylethanolammonium
57. Spbio_001975
58. Gtpl4551
59. Dtxsid8043789
60. Kbio1_000107
61. Kbio2_000738
62. Kbio2_003306
63. Kbio2_005874
64. Nsc6393
65. Ninds_000107
66. (2-hydroxyethyl)trimethyl Ammonium
67. Mono-2-hydroxyethyltrimethylammonium
68. Nsc-6393
69. Zinc3079337
70. Bbl005532
71. Bdbm50026220
72. Stl137772
73. Akos005721137
74. 2-hydroxyethyl)trimethylammonium
75. Ccg-204275
76. Db00122
77. Idi1_000107
78. Ncgc00015219-01
79. Ncgc00015219-02
80. Ncgc00015219-04
81. Ncgc00015219-07
82. Ncgc00015219-10
83. Ncgc00162082-01
84. Carbachol Impurity A [ep Impurity]
85. Sbi-0050168.p003
86. 2-hydroxy-n,n,n-trimethylammonium Chloride
87. (.beta.-hydroxyethyl)trimethylammonium
88. C00114
89. D07690
90. Ab00053822_02
91. Ethanaminium, 2-hydroxy-n,n,n-trimethyl- (9ci)
92. Q193166
93. Acetylcholine Chloride Impurity A [ep Impurity]
| Molecular Weight | 104.17 g/mol |
|---|---|
| Molecular Formula | C5H14NO+ |
| XLogP3 | -0.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 2 |
| Exact Mass | 104.107539070 g/mol |
| Monoisotopic Mass | 104.107539070 g/mol |
| Topological Polar Surface Area | 20.2 Ų |
| Heavy Atom Count | 7 |
| Formal Charge | 1 |
| Complexity | 46.5 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For nutritional supplementation, also for treating dietary shortage or imbalance
This compound is needed for good nerve conduction throughout the CNS (central nervous system) as it is a precursor to acetylcholine (ACh). Choline is also needed for gallbladder regulation, liver function and lecithin (a key lipid) formation. Choline also aids in fat and cholesterol metabolism and prevents excessive fat build up in the liver. Choline has been used to mitigate the effects of Parkinsonism and tardive dyskinesia. Choline deficiencies may result in excessive build-up of fat in the liver, high blood pressure, gastric ulcers, kidney and liver dysfunction and stunted growth.
Lipotropic Agents
Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues. (See all compounds classified as Lipotropic Agents.)
Nootropic Agents
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. (See all compounds classified as Nootropic Agents.)
Choline has known human metabolites that include Trimethylazanium and acetaldehyde.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Choline is a major part of the polar head group of phosphatidylcholine. Phosphatidylcholine's role in the maintenance of cell membrane integrity is vital to all of the basic biological processes: information flow, intracellular communication and bioenergetics. Inadequate choline intake would negatively affect all these processes. Choline is also a major part of another membrane phospholipid, sphingomyelin, also important for the maintenance of cell structure and function. It is noteworthy and not surprising that choline deficiency in cell culture causes apoptosis or programmed cell death. This appears to be due to abnormalities in cell membrane phosphatidylcholine content and an increase in ceramide, a precursor, as well as a metabolite, of sphingomyelin. Ceramide accumulation, which is caused by choline deficiency, appears to activate Caspase, a type of enzyme that mediates apoptosis. Betaine or trimethylglycine is derived from choline via an oxidation reaction. Betaine is one of the factors that maintains low levels of homocysteine by resynthesizing L-methionine from homocysteine. Elevated homocysteine levels are a significant risk factor for atherosclerosis, as well as other cardiovascular and neurological disorders. Acetylcholine is one of the major neurotransmitters and requires choline for its synthesis. Adequate acetylcholine levels in the brain are believed to be protective against certain types of dementia, including Alzheimer's disease.
PI Health Sciences: Biotech for Hire providing end-to-end discovery and development powered by chemistry, biology, and AI.
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7329
Submission : 1988-02-12
Status : Active
Type : II
NDC Package Code : 17381-251
Start Marketing Date : 2010-04-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16987
Submission : 2003-11-14
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20764
Submission : 2007-08-08
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22208
Submission : 2008-11-19
Status : Active
Type : II


GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27301
Submission : 2013-10-01
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7329
Submission : 1988-02-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27301
Submission : 2013-10-01
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4013
Submission : 1980-12-15
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24027
Submission : 2010-08-05
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16987
Submission : 2003-11-14
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22208
Submission : 2008-11-19
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20764
Submission : 2007-08-08
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3475
Submission : 1978-12-22
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3972
Submission : 1980-09-12
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-07-04
Valid Till : 2028-07-03
Written Confirmation Number : WC-0277
Address of the Firm : Block No. 588, Savli Karachia Road, At & Post-Gothada-391776, Tal- Savli, Dist- ...

Choline Salicylate Solution BP
Date of Issue : 2024-12-20
Valid Till : 2027-12-19
Written Confirmation Number : WC-0599
Address of the Firm : Plot No. 15B6, APSEZ, De- Notified Area, Atchutapuram, Krishnampalem (V), Rambil...

Choline Salicylate Solution BP
Date of Issue : 2022-08-29
Valid Till : 2025-07-26
Written Confirmation Number : WC-0180
Address of the Firm : D-123, Phase -III, IDA., Jeedimetla (V), Quthbullapur (M), Medchal-Malkajgiri Di...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
NDC Package Code : 17381-251
Start Marketing Date : 2010-04-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]VMF Number : 5889
Submission : 2007-04-17
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
PI Health Sciences: Biotech for Hire providing end-to-end discovery and development powered by chemistry, biology, and AI.
About the Company : PI Health Sciences offers end-to-end drug discovery and development, integrating medicinal chemistry, synthetic chemistry, biology, and AI-driven technologies. Its co-located teams...
About the Company : Minakem Montreal is developing and manufacturing small molecules APIs and advanced intermediates, including corticosteroids. Following efficient processes and methodologies, our em...
About the Company : Established in 1991, Pharm-Rx is an importer and distributor of active ingredients serving the pharmaceutical, nutritional supplement, and food industries. The company follows a hi...
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
About the Company : Siegfried is a global Contract Development and Manufacturing Organization providing integrated services for pharmaceutical ingredients & finished dosage forms. With 13 production s...
About the Company : AROCHEM INDUSTRIES is a firm incepted in the year 1978 and is engaged in the business of manufacture and sell specialty organic chemicals, bulk drugs and other organic intermediate...

About the Company : AROCHEM INDUSTRIES is a firm incepted in the year 1978 and is engaged in the business of manufacture and sell specialty organic chemicals, bulk drugs and other organic intermediate...

About the Company : AROCHEM INDUSTRIES is a firm incepted in the year 1978 and is engaged in the business of manufacture and sell specialty organic chemicals, bulk drugs and other organic intermediate...

About the Company : Jinan Pengbo Biotechnology Co., Ltd., founded in Jinan, capital of Shandong province since 2013. We are sales representive for our own factory: Jinan Jiuan Ester Chemical Co., Ltd....

About the Company : Kreative Organics Private Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs) for the world market. Kreative started operations in 1990. Kreative was established ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Phosphatidylcholine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Diseases.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2015
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
Details : Phosphatidylcholine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2015
Details:
Choline is a Dietary Supplement drug candidate, which is currently being evaluated for the treatment of Menopause.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Sponsor: BALCHEM
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2025

Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : BALCHEM
Deal Size : Inapplicable
Deal Type : Inapplicable
Choline and Brain Functioning in Postmenopausal Women
Details : Choline is a Dietary Supplement drug candidate, which is currently being evaluated for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor, it is being investigated for the treament of individuals with moderate to severe dry eye disease (DED).
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telios Announces Successful Phase 2 Results for TL-925, a Treatment for Dry Eye Disease
Details : TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor, it is being investigated for the treament of individuals with moderate to severe dry eye disease (DED).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Of TL-925 For The Treatment of AC
Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 01, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TL-925 for the Treatment of Allergic Conjunctivitis
Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2023

Details:
Choline is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Dietary Supplement
Sponsor: MD Anderson Cancer Center | Massachusetts Institute of Technology | BALCHEM
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2023

Choline Effects - Pre-symptomatic AD
Details : Choline is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 30, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Choline,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Choline,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TL-925 as a Treatment for Dry Eye Disease
Details : TL-925 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
WHITNEY JOHNS ACTIVE (lepidium meyenii root extract) proven all-natural BPF Gold Citrus Bergamot SuperFruit™ formulation, has been clinically proven to increase NO by 73% and oxygen consumption by 24%, thereby enhancing physical performance and the benefits of exercise.
Lead Product(s): Lepidium Meyenii Root Extract,Choline,Magnesium
Therapeutic Area: Musculoskeletal Brand Name: Active
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 22, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lepidium Meyenii Root Extract,Choline,Magnesium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Healthy Extracts’ WHITNEY JOHNS ACTIVE™ Clinically Proven to Enhance Physical Performance by I...
Details : WHITNEY JOHNS ACTIVE (lepidium meyenii root extract) proven all-natural BPF Gold Citrus Bergamot SuperFruit™ formulation, has been clinically proven to increase NO by 73% and oxygen consumption by 24%, thereby enhancing physical performance and the ben...
Product Name : Active
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 22, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OXTRIPHYLLINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 200MG
Packaging :
Approval Date : 1983-08-25
Application Number : 87835
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OXTRIPHYLLINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 100MG
Packaging :
Approval Date : 1983-08-25
Application Number : 87866
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : CHOLINE C-11
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 4-33.1mCi/ML
Packaging :
Approval Date : 2012-09-12
Application Number : 203155
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OXTRIPHYLLINE PEDIATRIC
Dosage Form : SYRUP;ORAL
Dosage Strength : 50MG/5ML
Packaging :
Approval Date : 1983-12-05
Application Number : 88242
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : OXTRIPHYLLINE
Dosage Form : SOLUTION;ORAL
Dosage Strength : 100MG/5ML
Packaging :
Approval Date : 1983-12-05
Application Number : 88243
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CHOLEDYL
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 100MG
Packaging :
Approval Date : 1982-01-01
Application Number : 9268
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CHOLEDYL
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 200MG
Packaging :
Approval Date : 1982-01-01
Application Number : 9268
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CHOLEDYL
Dosage Form : SYRUP;ORAL
Dosage Strength : 50MG/5ML
Packaging :
Approval Date : 1982-01-01
Application Number : 9268
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CHOLEDYL
Dosage Form : SOLUTION;ORAL
Dosage Strength : 100MG/5ML
Packaging :
Approval Date : 1984-11-27
Application Number : 9268
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CHOLEDYL SA
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 600MG
Packaging :
Approval Date : 1982-01-01
Application Number : 86742
Regulatory Info : DISCN
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : OXTRIPHYLLINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 200MG
Approval Date : 1983-08-25
Application Number : 87835
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : OXTRIPHYLLINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 100MG
Approval Date : 1983-08-25
Application Number : 87866
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AP
Brand Name : CHOLINE C-11
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 4-33.1mCi/ML
Approval Date : 2012-09-12
Application Number : 203155
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : OXTRIPHYLLINE PEDIATRIC
Dosage Form : SYRUP;ORAL
Dosage Strength : 50MG/5ML
Approval Date : 1983-12-05
Application Number : 88242
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : OXTRIPHYLLINE
Dosage Form : SOLUTION;ORAL
Dosage Strength : 100MG/5ML
Approval Date : 1983-12-05
Application Number : 88243
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CHOLEDYL
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 100MG
Approval Date : 1982-01-01
Application Number : 9268
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CHOLEDYL
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 200MG
Approval Date : 1982-01-01
Application Number : 9268
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CHOLINE C-11
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 4-100mCi/ML
Approval Date : 2015-10-29
Application Number : 205690
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CHOLEDYL SA
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 600MG
Approval Date : 1982-01-01
Application Number : 86742
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : CHOLEDYL SA
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 400MG
Approval Date : 1983-05-24
Application Number : 87863
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Ukraine
Brand Name : Product Under Development
Dosage Form : Capsule
Dosage Strength : 300MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Mundisal
Dosage Form : Gel
Dosage Strength : 87.1mg/g
Packaging :
Approval Date : 01/06/1967
Application Number : 33332
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Teovent
Dosage Form : Tablet
Dosage Strength : 135mg
Packaging :
Approval Date : 15-12-1978
Application Number : 1.98E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Teovent
Dosage Form : Oral Solution
Dosage Strength : 6.5mg/ml
Packaging :
Approval Date : 15-12-1978
Application Number : 1.98E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Teovent
Dosage Form : Rectal Solution
Dosage Strength : 50mg
Packaging :
Approval Date : 06-02-1981
Application Number : 1.98E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Teovent
Dosage Form : Rectal Solution
Dosage Strength : 100mg
Packaging :
Approval Date : 06-02-1981
Application Number : 1.98E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Teovent
Dosage Form : Rectal Solution
Dosage Strength : 250mg
Packaging :
Approval Date : 18-12-1981
Application Number : 1.98E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorised
Registration Country : Malta
Brand Name : Audax
Dosage Form : Ear Drop Suspension
Dosage Strength : 20%W/V
Packaging :
Approval Date : 2024-08-13
Application Number :
Regulatory Info : Authorised
Registration Country : Malta

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Faringodol Forte
Dosage Form : Lozenges
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorised
Registration Country : Malta
Cetalkonium Chloride; Choline Salicylate
Brand Name : Bonjela Oromucosal Gel
Dosage Form : Oromucosal Gel
Dosage Strength : 0.01%W/W; 8.714%W/W
Packaging :
Approval Date : 2006-04-24
Application Number :
Regulatory Info : Authorised
Registration Country : Malta

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Syrup
Grade : Oral
Application : Taste Masking
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Maltitol Excipient
Excipients Web Link
Dosage Form : Syrup
Grade : Oral and Topical
Application : Taste Masking
Excipients Web Link
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Market Place
Reply
21 Feb 2026
Reply
20 Aug 2025
Reply
06 Jun 2025
Reply
03 Mar 2025
Reply
25 Feb 2025
Reply
18 Dec 2024
Reply
16 May 2024
Reply
18 Oct 2023
Reply
02 Sep 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
22
PharmaCompass offers a list of Choline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Choline manufacturer or Choline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Choline manufacturer or Choline supplier.
PharmaCompass also assists you with knowing the Choline API Price utilized in the formulation of products. Choline API Price is not always fixed or binding as the Choline Price is obtained through a variety of data sources. The Choline Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Choline C-11 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Choline C-11, including repackagers and relabelers. The FDA regulates Choline C-11 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Choline C-11 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Choline C-11 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Choline C-11 supplier is an individual or a company that provides Choline C-11 active pharmaceutical ingredient (API) or Choline C-11 finished formulations upon request. The Choline C-11 suppliers may include Choline C-11 API manufacturers, exporters, distributors and traders.
click here to find a list of Choline C-11 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Choline C-11 DMF (Drug Master File) is a document detailing the whole manufacturing process of Choline C-11 active pharmaceutical ingredient (API) in detail. Different forms of Choline C-11 DMFs exist exist since differing nations have different regulations, such as Choline C-11 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Choline C-11 DMF submitted to regulatory agencies in the US is known as a USDMF. Choline C-11 USDMF includes data on Choline C-11's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Choline C-11 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Choline C-11 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Choline C-11 Drug Master File in Japan (Choline C-11 JDMF) empowers Choline C-11 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Choline C-11 JDMF during the approval evaluation for pharmaceutical products. At the time of Choline C-11 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Choline C-11 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Choline C-11 Drug Master File in Korea (Choline C-11 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Choline C-11. The MFDS reviews the Choline C-11 KDMF as part of the drug registration process and uses the information provided in the Choline C-11 KDMF to evaluate the safety and efficacy of the drug.
After submitting a Choline C-11 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Choline C-11 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Choline C-11 suppliers with KDMF on PharmaCompass.
A Choline C-11 written confirmation (Choline C-11 WC) is an official document issued by a regulatory agency to a Choline C-11 manufacturer, verifying that the manufacturing facility of a Choline C-11 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Choline C-11 APIs or Choline C-11 finished pharmaceutical products to another nation, regulatory agencies frequently require a Choline C-11 WC (written confirmation) as part of the regulatory process.
click here to find a list of Choline C-11 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Choline C-11 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Choline C-11 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Choline C-11 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Choline C-11 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Choline C-11 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Choline C-11 suppliers with NDC on PharmaCompass.
Choline C-11 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Choline C-11 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Choline C-11 GMP manufacturer or Choline C-11 GMP API supplier for your needs.
A Choline C-11 CoA (Certificate of Analysis) is a formal document that attests to Choline C-11's compliance with Choline C-11 specifications and serves as a tool for batch-level quality control.
Choline C-11 CoA mostly includes findings from lab analyses of a specific batch. For each Choline C-11 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Choline C-11 may be tested according to a variety of international standards, such as European Pharmacopoeia (Choline C-11 EP), Choline C-11 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Choline C-11 USP).